Toll-like Receptors

Loxoribine, a guanosine analog, functions as a selective Toll-like receptor (TLR) 7 agonist. This compound exhibits significant anti-viral and anti-tumor activities, making it valuable for research applications in immunotherapy and cancer treatment. Its oral bioavailability expands its potential for in vivo studies.

DSR-6434 is a highly potent and selective agonist of Toll-like receptor 7 (TLR7), exhibiting EC50 values of 7.2 nM for human TLR7 and 4.6 nM for mouse TLR7. This compound demonstrates significant antitumor activity, making it a valuable tool for studying cancer immunotherapy and TLR7 signaling pathways in various research applications.

CL264 is a selective agonist of Toll-like receptor 7 (TLR7), primarily utilized for examining innate immune signaling pathways. This compound enhances the activation of immune responses through TLR7 stimulation, making it a valuable tool for research in immunology and inflammation. Its application extends to understanding the mechanisms of antiviral responses and potential therapeutic strategies targeting TLR-mediated immune modulation.

TLR7/8/9-IN-1 is a potent small molecule antagonist targeting Toll-like receptors 7, 8, and 9, with an IC50 value of 43 nM. This compound effectively inhibits TLR-mediated signaling pathways, playing a crucial role in the immune response. It is valuable for research applications focused on inflammatory diseases, autoimmune disorders, and the modulation of innate immunity.

CpG ODN 10101 is a TLR9 agonist, designed as a synthetic oligodeoxynucleotide modified with phosphate thioester. This compound activates B cells and plasmacytoid dendritic cells, leading to enhanced production of cytokines and chemokines, including interferon-α and IP-10. By modulating innate immunity and promoting Th1 adaptive responses, CpG ODN 10101 demonstrates antiviral properties and enhances vaccine immunogenicity, highlighting its potential as an immunomodulator and vaccine adjuvant in the development of therapies for chronic hepatitis C and various infectious diseases.

CAY10614 is a potent TLR4 antagonist that inhibits lipid A-induced activation of the TLR4 receptor, exhibiting an IC50 of 1.675 μM. This compound has demonstrated the ability to improve survival rates in mouse models of lethal endotoxin shock. CAY10614 is valuable for research applications investigating TLR4-mediated inflammatory responses and the development of therapeutic strategies targeting sepsis and other endotoxin-related conditions.

CPG-52364 is a TLR9 antagonist that exhibits inhibitory activity against TLR9 in the HEK293-hTLR9 cell line, with an IC50 value of 4.6 nM. This compound is valuable for research applications investigating immune response modulation, particularly in studies related to autoimmune diseases and inflammation. Its specificity for TLR9 makes it a useful tool for exploring the therapeutic potential of TLR modulation in various biological contexts.

CL097 hydrochloride is a potent agonist of Toll-like receptors 7 and 8 (TLR7/8) that activates pro-inflammatory cytokine production in macrophages. This compound also facilitates NADPH oxidase priming, leading to enhanced reactive oxygen species (ROS) generation upon fMLF stimulation. CL097 is valuable in research applications related to immune response and inflammation.